Results demonstrate that the company’s lead vaccine candidate can direct a comprehensive immune response against ovarian tumor cells and induce the formation of memory T cells
Leiden, The Netherlands, November 9, 2020 – DCprime, the front-runner in the field of relapse vaccines, today announced the presentation of preclinical results at the virtual 35th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), occurring November 9-14. The in vitro and in vivo data presented at SITC highlight the potential impact of the company’s lead vaccine candidate, DCP-001, on ovarian cancer treatment and post-remission therapy. The accepted abstract is listed below and is now available online on the SITC website.
“We are approaching a pivotal time for DCprime in which we will be generating a growing body of preclinical data showing the potential of our vaccination approach in solid tumors in addition to first clinical data emerging from our ongoing ADVANCE II clinical study in Acute Myeloid Leukemia (AML) patients before year-end. Both developments are of equal importance for us today with the high unmet medical need in solid tumors being a significant long-term opportunity for value generation,” commented Erik Manting, PhD, CEO of DCprime.
The preclinical studies presented at SITC are based on a successful research collaboration between DCprime and the Department of Obstetrics and Gynecology of the University Medical Center of Groningen (UMCG), led by Professor Hans Nijman, MD, PhD. Animal studies were carried out in collaboration with TransCure Bioservices SAS, supported by a Eurostars funding.
In peripheral blood mononuclear cells from healthy donors and ovarian cancer patients, DCP-001 was shown to activate both T helper cells (CD4+) as well as cytotoxic T cells (CD8+) and was able to induce the formation of memory T cells. Importantly, CD8+ T cells derived from ovarian cancer patients stimulated by DCP-001 were shown to exert an elevated cytotoxic immune response to ovarian cancer cells. In a humanized mouse model for ovarian cancer, relapse vaccination with DCP-001, lead to a significant reduction of tumor growth, including partial and complete tumor regressions. Based on the promising preclinical data, DCprime is currently preparing together with the Nijman group at UMCG a Phase I clinical trial in ovarian cancer patients.
Poster Presentation Details:
Presentation Title: #171: Preclinical studies support therapeutic application of the leukemic cell-based cancer relapse vaccine DCP-001 in ovarian cancer
Maho Nagasawa; Remco Bos; Haoxiao Zuo; Kiave Yune Ho Wang Yin; Marie-José van Lierop; Sebastien Tabruyn; Erik Manting; Marco de Bruyn; Hans Nijman; Satwinder Kaur SK. Singh.
The poster’s authors will be available for the Virtual Poster Viewing sessions to answer questions and interact with meeting attendees in real time on Wednesday, November 11 from 5:15–5:45 p.m. EST and Friday, November 13 from 4:40–5:10 p.m. EST.
About DCprime
DCprime is the front-runner in the field of relapse vaccines, a new class of oncology vaccines administered after or in conjunction with standard of care therapy to delay or prevent disease recurrence. Our lead product is a whole-cell-based vaccine addressing blood cancers with a high risk of relapse. We are pursuing similar vaccination approaches for solid tumors. We believe relapse vaccines will improve survival by putting the patient’s immune system back in control. For more information, please visit: https://dcprime.com/
Contact Information:
DCprime BV
Dr. Erik Manting, CEO
Phone: +31 713322627
Email: e.manting@dcprime.com
Media Contact:
Mario Brkulj or Nicholas Chang
MacDougall
Phone: +49 175 5711562 or +1 781 235 3060
E-Mail: dcprime@macbiocom.com